Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Alzheimers Dement. 2010 Jul;6(4):334-41. doi: 10.1016/j.jalz.2009.09.001.
The prevalence and expenditure estimates of Alzheimer's disease (AD) from studies using one data source to define cases vary widely. The objectives of this study were to assess agreement between AD case definitions classified with Medicare claims and survey data and to provide insight into causes of widely varied expenditure estimates.
Data were obtained from the 1999-2004 Medicare Current Beneficiary Survey linked with Medicare claims (n = 57,669). Individuals with AD were identified by survey, diagnosis, use of an AD prescription medicine, or some combination thereof. We also explored how much health care and drug expenditures vary by AD case definition.
The prevalence of AD differed significantly by case definition. Using survey report alone yielded more cases (n = 1,994 or 3.46%) than diagnosis codes alone (n = 1,589 or 2.76%) or Alzheimer's medication use alone (n = 1,160 or 2.01%). Agreement between case definitions was low, with kappa coefficients ranging from 0.37 to 0.40. Per capita health expenditures ranged from $16,547 to $24,937, and drug expenditures ranged from $2,303 to $3,519, depending on how AD was defined.
Different information sources yield widely varied prevalence and expenditure estimates. Although claims data provided a more objective means for identifying AD cases, survey report identified more cases, and pharmacy data also are an important source for case ascertainment. Using any single source will underestimate the prevalence and associated cost of AD. The wide range of AD cases identified by using different data sources demands caution interpreting cost-of-illness studies using single data sources.
使用单一数据源定义病例的阿尔茨海默病(AD)患病率和支出估计值差异很大。本研究的目的是评估使用医疗保险索赔和调查数据分类的 AD 病例定义之间的一致性,并深入了解支出估计值差异很大的原因。
数据来自 1999-2004 年医疗保险当前受益人体检调查,与医疗保险索赔数据相关联(n=57669)。通过调查、诊断、使用 AD 处方药或其组合来确定 AD 患者。我们还探讨了不同 AD 病例定义对医疗保健和药物支出的影响。
AD 的患病率因病例定义而异。仅使用调查报告就比仅使用诊断代码(n=1589 或 2.76%)或仅使用阿尔茨海默氏症药物(n=1160 或 2.01%)发现更多的病例(n=1994 或 3.46%)。病例定义之间的一致性较低,kappa 系数范围为 0.37 至 0.40。人均医疗支出从 16547 美元到 24937 美元不等,药物支出从 2303 美元到 3519 美元不等,具体取决于 AD 的定义方式。
不同的信息来源产生了广泛不同的患病率和支出估计值。虽然索赔数据提供了一种更客观的识别 AD 病例的方法,但调查报告确定了更多的病例,而药房数据也是病例确定的重要来源。仅使用单一来源将低估 AD 的患病率和相关成本。使用不同数据源确定的 AD 病例范围广泛,这要求在使用单一数据源的疾病成本研究中谨慎解释结果。